ALTB-268: Phase 1 Topline Data of Novel Immune Checkpoint Enhancer for the treatment of Ulcerative Colitis
ALTB-268 was well tolerated with no serious adverse events across all subject cohorts. In addition, ALTB-268 demonstrated substantially greater biological activity than first ICE molecule, ALTB-168, enabling subcutaneous administration.